Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Papillary renal cell carcinoma, sporadic, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, hereditary leiomyomatosis and renal cell cancer, kidney cancer, kidney disorder, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, urinary system disorder	Recruiting	Phase 2	2026-09-29		NCT04981509

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Emory Saint Joseph's Hospital	Atlanta	United States	175
Emory University Hospital Midtown	Atlanta	United States	246
Emory University Hospital/Winship Cancer Institute	Atlanta	United States	299
Laura and Isaac Perlmutter Cancer Center at NYU Langone	New York	United States	188
National Institutes of Health Clinical Center	Bethesda	United States	800
NCI - Center for Cancer Research	Bethesda	United States	13
Northwestern University	Chicago	United States	727
NYU Langone Hospital - Long Island	Mineola	United States	107
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
Rutgers Cancer Institute of New Jersey	New Brunswick	United States	223
UC San Diego Moores Cancer Center	La Jolla	United States	199
UPMC Hillman Cancer Center	Pittsburgh	United States	330
UT MD Anderson Cancer Center	Houston	United States	204